Compare BridgeBio Pharma Inc (BBIO) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.9. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | JNK | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $98.19 |
52-Week Low | $44.81 | $94.66 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
JNK trades at $95.76, down 0.18% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF maintains consistent dividend distributions, with recent payouts around $0.52-$0.53. Market sentiment is cautious amid Federal Reserve uncertainty and inflation concerns, while technical support sits near $95.
The outlook for JNK is clouded by potential Fed rate hikes and bond market volatility. High-yield bond ETFs face headwinds from rising yields, though demand for yield remains strong. Risks include interest rate sensitivity and economic slowdowns, while institutional flows indicate mixed confidence in fixed income assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
